South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs
Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) target a specific pathway of the immune system, and are usually prescribed after failure of conventional synthetic disease-modifying antirheumatic drug therapy. The choice of b/tsDMARD depends on the disease...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South African Medical Association
2024-09-01
|
| Series: | South African Medical Journal |
| Subjects: | |
| Online Access: | https://samajournals.co.za/index.php/samj/article/view/2599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860592490840064 |
|---|---|
| author | E van Duuren J Potts U Brijlal S Botha S Didi K Makan M van Dam K Chinniah B Hodkinson |
| author_facet | E van Duuren J Potts U Brijlal S Botha S Didi K Makan M van Dam K Chinniah B Hodkinson |
| author_sort | E van Duuren |
| collection | DOAJ |
| description |
Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) target a specific pathway of the immune system, and are usually prescribed after failure of conventional synthetic disease-modifying antirheumatic drug therapy. The choice of b/tsDMARD depends on the disease profile and comorbidities, patient preference, registered indications of the drugs, and risks associated with therapy. It is recommended that b/tsDMARDs for immune-mediated inflammatory rheumatic diseases are prescribed by a rheumatologist, and all patients must be included in the South African Rheumatism and Arthritis Association biologic registry. Knowledge of and vigilance for adverse events, particularly infections, associated with b/ts DMARD therapies are of paramount importance.
|
| format | Article |
| id | doaj-art-a335d9f4c45948f2983e0551f3612ac5 |
| institution | Kabale University |
| issn | 0256-9574 2078-5135 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | South African Medical Association |
| record_format | Article |
| series | South African Medical Journal |
| spelling | doaj-art-a335d9f4c45948f2983e0551f3612ac52025-02-10T12:25:39ZengSouth African Medical AssociationSouth African Medical Journal0256-95742078-51352024-09-01114910.7196/SAMJ.2024.v114i10.2599South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugsE van Duuren0J Potts1U Brijlal2S Botha3S Didi4K Makan5M van Dam6K Chinniah7B Hodkinson8Jacaranda Hospital, Pretoria, South AfricaNetcare Greenacres Hospital, Gqeberha, South AfricaMediclinic Milnerton, Cape Town, South AfricaMediclinic Winelands Orthopaedic Hospital, Stellenbosch, South AfricaRheumatology Division, Department of Medicine, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, South AfricaDepartment of Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, JohannesburgAxial Spondyloarthritis Association of South AfricaAhmed Al-Kadi Private Hospital, Durban, South AfricaRheumatology Division, Department of Medicine, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, South Africa Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) target a specific pathway of the immune system, and are usually prescribed after failure of conventional synthetic disease-modifying antirheumatic drug therapy. The choice of b/tsDMARD depends on the disease profile and comorbidities, patient preference, registered indications of the drugs, and risks associated with therapy. It is recommended that b/tsDMARDs for immune-mediated inflammatory rheumatic diseases are prescribed by a rheumatologist, and all patients must be included in the South African Rheumatism and Arthritis Association biologic registry. Knowledge of and vigilance for adverse events, particularly infections, associated with b/ts DMARD therapies are of paramount importance. https://samajournals.co.za/index.php/samj/article/view/2599targeted synthetic therapybiologicSouth Africa |
| spellingShingle | E van Duuren J Potts U Brijlal S Botha S Didi K Makan M van Dam K Chinniah B Hodkinson South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs South African Medical Journal targeted synthetic therapy biologic South Africa |
| title | South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs |
| title_full | South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs |
| title_fullStr | South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs |
| title_full_unstemmed | South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs |
| title_short | South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs |
| title_sort | south african rheumatism and arthritis association 2024 guidelines for the use of biologic and targeted synthetic disease modifying antirheumatic drugs |
| topic | targeted synthetic therapy biologic South Africa |
| url | https://samajournals.co.za/index.php/samj/article/view/2599 |
| work_keys_str_mv | AT evanduuren southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT jpotts southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT ubrijlal southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT sbotha southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT sdidi southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT kmakan southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT mvandam southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT kchinniah southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs AT bhodkinson southafricanrheumatismandarthritisassociation2024guidelinesfortheuseofbiologicandtargetedsyntheticdiseasemodifyingantirheumaticdrugs |